Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial.

Masaki Kato,Kazuyuki Nakagome,Takamichi Baba,Takuhiro Sonoyama,Daiki Okutsu, Hideki Yamanaka,Ryosuke Shimizu,Tomoko Motomiya,Takeshi Inoue

Psychiatry and clinical neurosciences（2023）

引用 4|浏览6

暂无评分

摘要

Oral zuranolone was safe and demonstrated significant improvements in depressive symptoms, as assessed by HAMD-17 total score change from baseline over 14 days in Japanese patients with MDD. This article is protected by copyright. All rights reserved.

查看译文

关键词

zuranolone,major depressive disorder,japanese adults

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要